메뉴 건너뛰기
Journal of the Canadian Urological Association
Volumn 7, Issue 11-12, 2013, Pages
The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84887349816     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.1447     Document Type: Article
Times cited : (31)
References (23)
  • 2
    • 3242766099 scopus 로고    scopus 로고
    • Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy
    • Stephenson AJ, Chetner MP, Rourke K, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004;172:58-62. http://dx.doi. org/10.1097/01.ju.0000132126.85812.7d
    • (2004) J Urol , vol.172 , pp. 58-62
    • Stephenson, A.J.1    Chetner, M.P.2    Rourke, K.3
  • 3
    • 10344224583 scopus 로고    scopus 로고
    • A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma
    • Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51. http://dx.doi. org/10.1097/01.ju.0000148261.19532.2c
    • (2005) J Urol , vol.173 , pp. 48-51
    • Sorbellini, M.1    Kattan, M.W.2    Snyder, M.E.3
  • 4
    • 33846026396 scopus 로고    scopus 로고
    • Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: The D-SSIGN score
    • Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007;177:477-80. http:// dx.doi.org/10.1016/j.juro.2006.09.057
    • (2007) J Urol , vol.177 , pp. 477-480
    • Thompson, R.H.1    Leibovich, B.C.2    Lohse, C.M.3
  • 5
    • 0036895290 scopus 로고    scopus 로고
    • Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
    • Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66. http://dx.doi.org/10.1200/JCO.2002.05.111
    • (2002) J Clin Oncol , vol.20 , pp. 4559-4566
    • Zisman, A.1    Pantuck, A.J.2    Wieder, J.3
  • 6
    • 69549097703 scopus 로고    scopus 로고
    • New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes
    • Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5. http://dx.doi. org/10.2337/dc08-2175
    • (2009) Diabetes Care , vol.32 , pp. 1620-1625
    • Libby, G.1    Donnelly, L.A.2    Donnan, P.T.3
  • 7
    • 67749144226 scopus 로고    scopus 로고
    • Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer
    • Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-02. http://dx.doi. org/10.1200/JCO.2009.19.6410
    • (2009) J Clin Oncol , vol.27 , pp. 3297-3302
    • Jiralerspong, S.1    Palla, S.L.2    Giordano, S.H.3
  • 8
    • 33751284806 scopus 로고    scopus 로고
    • Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
    • Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73. http://dx.doi.org/10.1158/0008-5472.CAN-06-1500
    • (2006) Cancer Res , vol.66 , pp. 10269-10273
    • Zakikhani, M.1    Dowling, R.2    Fantus, I.G.3
  • 9
    • 34547114031 scopus 로고    scopus 로고
    • Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
    • Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52. http://dx.doi. org/10.1158/0008-5472.CAN-06-4447
    • (2007) Cancer Res , vol.67 , pp. 6745-6752
    • Buzzai, M.1    Jones, R.G.2    Amaravadi, R.K.3
  • 10
    • 84875278034 scopus 로고    scopus 로고
    • Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft
    • Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013;31:264-70. http://dx.doi.org/10.1016/j.urolonc.2011.01.003. Epub 2011 Jun 15.
    • (2013) Urol Oncol , vol.31 , pp. 264-270
    • Liu, J.1    Li, M.2    Song, B.3
  • 11
    • 77954818058 scopus 로고    scopus 로고
    • The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM
    • Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
    • (2010) Ann Surg Oncol , vol.17 , pp. 1471-1474
    • Edge, S.B.1    Compton, C.C.2
  • 13
    • 35548999608 scopus 로고    scopus 로고
    • AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner
    • Sun Y, Connors KE, Yang DQ. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem 2007;306:239-45. http://dx.doi.org/10.1007/s11010-007-9575-6
    • (2007) Mol Cell Biochem , vol.306 , pp. 239-245
    • Sun, Y.1    Connors, K.E.2    Yang, D.Q.3
  • 14
    • 2942544833 scopus 로고    scopus 로고
    • Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells
    • Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63. http://dx.doi.org/10.1016/j.ccr.2004.05.024
    • (2004) Cancer Cell , vol.5 , pp. 553-563
    • Avdulov, S.1    Li, S.2    Michalek, V.3
  • 15
    • 24944480788 scopus 로고    scopus 로고
    • The Akt-mTOR tango and its relevance to cancer
    • Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83. http://dx.doi. org/10.1016/j.ccr.2005.08.008
    • (2005) Cancer Cell , vol.8 , pp. 179-183
    • Hay, N.1
  • 16
    • 25444524850 scopus 로고    scopus 로고
    • Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity
    • Hahn-Windgassen A, Nogueira V, Chen CC, et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9. http://dx.doi. org/10.1074/jbc.M502876200
    • (2005) J Biol Chem , vol.280 , pp. 32081-32089
    • Hahn-Windgassen, A.1    Nogueira, V.2    Chen, C.C.3
  • 17
    • 77955287742 scopus 로고    scopus 로고
    • Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPasedependent manner
    • Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPasedependent manner. Cell Metab 2010;11:390-401. http://dx.doi.org/10.1016/j.cmet.2010.03.014
    • (2010) Cell Metab , vol.11 , pp. 390-401
    • Kalender, A.1    Selvaraj, A.2    Kim, S.Y.3
  • 18
    • 33846866035 scopus 로고    scopus 로고
    • The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
    • Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13:758s-763s. http://dx.doi.org/10.1158/1078-0432.CCR-06-1986
    • (2007) Clin Cancer Res , vol.13
    • Cho, D.1    Signoretti, S.2    Regan, M.3
  • 19
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. http://dx.doi.org/10.1056/NEJMoa066838
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 20
    • 79951708837 scopus 로고    scopus 로고
    • Metformin and cancer occurrence in insulin-treated type 2 diabetic patients
    • Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34:129-31. http://dx.doi.org/10.2337/dc10-1287
    • (2011) Diabetes Care , vol.34 , pp. 129-131
    • Monami, M.1    Colombi, C.2    Balzi, D.3
  • 21
    • 84857372409 scopus 로고    scopus 로고
    • Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
    • Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012;118:1202-11. http://dx.doi.org/10.1002/ cncr.26439
    • (2012) Cancer , vol.118 , pp. 1202-1211
    • Bayraktar, S.1    Hernadez-Aya, L.F.2    Lei, X.3
  • 22
    • 23844438209 scopus 로고    scopus 로고
    • Activation of Akt and eIF4E survival pathways by rapamycinmediated mammalian target of rapamycin inhibition
    • Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycinmediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8. http://dx.doi. org/10.1158/0008-5472.CAN-05-0917
    • (2005) Cancer Res , vol.65 , pp. 7052-7058
    • Sun, S.Y.1    Rosenberg, L.M.2    Wang, X.3
  • 23
    • 84863116501 scopus 로고    scopus 로고
    • mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
    • Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012;11:594-603. http://dx.doi.org/10.4161/cc.11.3.19096
    • (2012) Cell Cycle , vol.11 , pp. 594-603
    • Zhang, Y.1    Zheng, X.F.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.